Navigation Links
Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
Date:3/27/2013

tudy is predicated on a prospective subgroup analysis conducted in the Phase 2b PEARL-SC study, which was reported in July 2012. In this analysis, a significant improvement in SRI-8 was observed in patients who received subcutaneous blisibimod (200mg QW) compared to those treated standard steroid therapy (N=95, 41.7% versus 10.4% respectively, p<0.001). This finding was corroborated by the separate analysis of SRI-8 responder rates conducted in the entire study population (N=547). The CHABLIS-SC1 study was reviewed by the US Food and Drug Administration as part of an "End of Phase 2" meeting in September 2012.

"The initiation of the CHABLIS-SC1 study marks a critical milestone for Anthera. The insight from our Phase 2b clinical study supports our belief that blisibimod may be a highly effective treatment option for the more severely ill lupus patients compared to currently available therapeutics," said Colin Hislop , MD, Anthera's Chief Medical Officer. "We are excited to advance blisibimod's development. Today we have taken another step towards making a much needed treatment available for this unpredictable and devastating disease."

About B-Cell Activating Factor (BAFF) and blisibimod

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on the potential positive role on BAFF inhibitors in treating lupus and rheumatoid arthritis with concomitant decreases in B-cells, plasma cells and autoantibodies. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel protein compromised of high-affinity BAFF binding domains fused to a human Fc domain,
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014  Over 200 patients, families, physicians ... to learn, interact and participate in the drive ... Lupus Trials Fair launched by the Lupus ... Lupus Foundation .  Attendees interacted directly with researchers ... experiences, ideas and needs and learning about more ...
(Date:9/15/2014)... 2014 Biomerics LLC, a leading provider ... announced its merger with Access Point Technologies and ... division was formed to provide next generation catheter ... structure heart, interventional radiology, interventional cardiology, and neurovascular ... will be led by Steve Berhow , ...
(Date:9/15/2014)... 2014 Chek Diagnostics, the U.S.-based manufacturer of ... point-of-care diagnostic products, has again been named to the ... companies in America. The Inc. 5000 ranking ... Chek Diagnostics earned its place on the list by ... 2013. For Chek Diagnostics, who appears on ...
Breaking Medicine Technology:Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3Biomerics and Access Point Technologies OEM Announce Merger and Creation of Biomerics Advanced Catheter Division 2Chek Diagnostics Named to Inc. Magazine's 5000 Fastest Growing Private Companies List for the Fourth Time 2Chek Diagnostics Named to Inc. Magazine's 5000 Fastest Growing Private Companies List for the Fourth Time 3
(Date:9/15/2014)... News) -- Births of multiple babies cost more and ... births, researchers report. The researchers suggest that limiting ... could ease some of that burden. Over the ... with births to older mothers and use of assisted ... New South Wales, Australia. Their study, published online ...
(Date:9/15/2014)... 15, 2014 As Colorado's historic ... its first full year, there are a variety ... in the evolution of its marketing and branding. ... taken by Denver's Kindman, one of the state's ... , Kindman has pioneered the first-ever branded and ...
(Date:9/15/2014)... September 15, 2014 According to a ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... was valued at USD 12,212.9 million in 2013 and ... at a CAGR of 7.2% from 2014 to 2020. ... properties of light within specific electromagnetic spectrum to identify ...
(Date:9/15/2014)... New York (PRWEB) September 15, 2014 ... in U.S. courts, Bernstein Liebhard LLP notes that a ... be useful in curbing aggression in children with ADHD ... and parent training in behavioral management techniques. According to ... children with ADHD and aggression problems, half of whom ...
(Date:9/15/2014)... Adding chest radiation to chemotherapy allows some people with ... rates by nearly 50 percent, European researchers report. ... researchers recommended that chest radiotherapy be routinely offered to ... chemotherapy. , , Small-cell lung cancer (SCLC) is an ... 13 percent of all lung cancers. For most people, ...
Breaking Medicine News(10 mins):Health News:Study Ties Multiple Births to Higher Costs, Complications 2Health News:Study Ties Multiple Births to Higher Costs, Complications 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 2Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 3Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 4Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 5Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 2Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 4Health News:Chest Radiation May Help Fight Some Advanced Lung Cancers: Study 2Health News:Chest Radiation May Help Fight Some Advanced Lung Cancers: Study 3
... finds these doctors have better results, including survival rates ... surgeons may be the best choice for adults requiring ... study suggests. , A congenital heart defect occurs when ... vessels near the heart. , The researchers analyzed a ...
... researchers from,Wayne State University, in collaboration with Basrah Medical ... New Iraqi Journal of,Medicine today on war-related mental health ... Bengt B. Arnetz, Ph.D., professor of Family Medicine and ... State University led the team,of researchers to conduct a ...
... cardiac valves years later , , FRIDAY, Nov. 7 (HealthDay News) ... help fight obesity has been tied to heart value damage ... a new study reports. , The appetite suppressant fenfluramine ... of its links to heart damage. Thousands of lawsuits have ...
... Triple-S,Management Corporation (NYSE: GTS ) today ... Officer, and Juan-Jose Roman,Finance Vice President & CFO, ... Credit Suisse 2008 Healthcare Conference in Phoenix on,November ... presentation will be,broadcast live through the Internet. You ...
... by a tumor or injury carry a severe psychological and ... in plastic surgery. Helmut Fischer and Wolfgang Gubisch present the ... of Deutsches rzteblatt International ( Dtsch Arztebl Int ... a woman who had had a tumor removed from the ...
... Events Held in Los Angeles Area Enable Medicare,Beneficiaries ... Period, SAN FRANCISCO, Nov. 7 Helping ... of California is offering,free "Fitness and Flexibility" events ... month. The events will offer a demonstration of ...
Cached Medicine News:Health News:Pediatric Heart Surgeons May Be Best Choice for Adults 2Health News:First Study of War-Related Mental Disorders Among Iraqis 10 Years Post-Gulf War Published by Researchers at Wayne State University and Basrah University, Iraq 2Health News:Banned Obesity Drug Tied to Heart Risks Long After Use 2Health News:Triple-S Management Corporation to Present at Credit Suisse 2008 Healthcare Conference 2Health News:Medicare Beneficiaries Can Suit Up, Sweat, and Learn About Blue Shield's Medicare Advantage Plans at Local Malls and Senior Centers 2Health News:Medicare Beneficiaries Can Suit Up, Sweat, and Learn About Blue Shield's Medicare Advantage Plans at Local Malls and Senior Centers 3Health News:Medicare Beneficiaries Can Suit Up, Sweat, and Learn About Blue Shield's Medicare Advantage Plans at Local Malls and Senior Centers 4Health News:Medicare Beneficiaries Can Suit Up, Sweat, and Learn About Blue Shield's Medicare Advantage Plans at Local Malls and Senior Centers 5
Relocatable frame has been designed specifically for fractionated stereotactic radiotherapy treatments. It provides a fast, non-invasive and reproducible fixation of the patient....
The unique MR-frame and its indicators are made of a highly tensile and fibre reenforced Epoxyd material....
VG2 PLIF (Parallel) Posterior lumbar interbody fusion. Frozen preservation. Consists of two outer cortical planks, center cancellous plank, all from the same donor, held together by two press-fit cor...
An all-cortical structure provides the structural benefits of cortical bone. Precision machined to exact specifications to promote healthy lordosis and vertebral body distraction....
Medicine Products: